Effect of Omalizumab on Blood Basophil Counts in Patients with Chronic Idiopathic/Spontaneous Urticaria

J Invest Dermatol. 2017 Apr;137(4):958-961. doi: 10.1016/j.jid.2016.11.025. Epub 2016 Dec 6.

Authors

Sarbjit S Saini¹, Theodore A Omachi², Benjamin Trzaskoma², Henry N Hulter², Karin Rosén², Patricia M Sterba¹, Jean-Paul Courneya¹, Alan Lackey³, Hubert Chen⁴

Affiliations

¹ Johns Hopkins Asthma and Allergy Center, Baltimore, Maryland, USA.
² Genentech, Inc., South San Francisco, California, USA.
³ LabCorp Clinical Trials, Brentwood, Tennessee, USA.
⁴ Genentech, Inc., South San Francisco, California, USA. Electronic address: chenh37@gene.com.

PMID: 27939380
DOI: 10.1016/j.jid.2016.11.025

No abstract available

Publication types

Letter
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Anti-Allergic Agents / therapeutic use*
Basophils / physiology*
Chronic Disease
Humans
Leukocyte Count
Omalizumab / therapeutic use*
Prospective Studies
Urticaria / blood
Urticaria / drug therapy*
Urticaria / etiology

Substances

Anti-Allergic Agents
Omalizumab

Associated data

ClinicalTrials.gov/NCT01287117
ClinicalTrials.gov/NCT01292473
ClinicalTrials.gov/NCT01264939